Home › Research › Inflammation and the immune system
Functional roles of reactive astrocytes in neuroinflammation and neurodegeneration
Patani R, Hardingham GE, Liddelow SA.. Nature reviews. Neurology, 2023-06-12
Topic: Brain proteins, microglia and lab models
Plain-language summary
Despite advances in uncovering the mechanisms that underlie neuroinflammation and neurodegenerative disease, therapies that prevent neuronal loss remain elusive. Targeting of disease-defining markers in conditions such as Alzheimer disease (amyloid-β and tau) or Parkinson disease (α-synuclein) has been met with limited success, suggesting that these proteins do not act in isolation but form part of a pathological network. This network could involve phenotypic alteration of multiple cell types in the CNS, including astrocytes, which have a major neurosupportive, homeostatic role in the healthy CNS but adopt reactive states under acute or chronic adverse conditions.
What this study adds
Evidence grade: Low
This is a narrative review. This review argues that because targeting amyloid-β and tau has "been met with limited success," these proteins likely act within a wider disease network, one that "could involve" astrocytes, brain support cells that "adopt reactive states" under stress. It reports that gene-activity studies in patients and disease models point to "many putative reactive sub-states" of astrocytes, and that how far these are shared across diseases "is unclear." It is a review with no new data and reports no treatment, cure or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Patani, R., Hardingham, G. E., & Liddelow, S. A. (2023). Functional roles of reactive astrocytes in neuroinflammation and neurodegeneration. Nature reviews. Neurology. https://doi.org/10.1038/s41582-023-00822-1
Vancouver
Patani R, Hardingham GE, Liddelow SA. Functional roles of reactive astrocytes in neuroinflammation and neurodegeneration. Nature reviews. Neurology. 2023. doi:10.1038/s41582-023-00822-1. PMID: 37308616.
BibTeX
@article{patani2023-37308616,
author = {Patani, R. and Hardingham, G. E. and Liddelow, S. A.},
title = {{Functional roles of reactive astrocytes in neuroinflammation and neurodegeneration}},
journal = {Nature reviews. Neurology},
year = {2023},
doi = {10.1038/s41582-023-00822-1},
pmid = {37308616},
url = {https://doi.org/10.1038/s41582-023-00822-1}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Targeting of disease-defining markers in conditions such as Alzheimer disease (amyloid-β and tau) or Parkinson disease (α-synuclein) has been met with limited success, suggesting that these proteins do not act in isolation but form part of a pathological network.
- This network could involve phenotypic alteration of multiple cell types in the CNS, including astrocytes, which have a major neurosupportive, homeostatic role in the healthy CNS but adopt reactive states under acute or chronic adverse conditions.
- Transcriptomic studies in human patients and disease models have revealed the co-existence of many putative reactive sub-states of astrocytes.
- Inter-disease and even intra-disease heterogeneity of reactive astrocytic sub-states are well established, but the extent to which specific sub-states are shared across different diseases is unclear.
Why it matters
This review argues that because targeting amyloid-β and tau has "been met with limited success," these proteins likely act within a wider disease network, one that "could involve" astrocytes, brain support cells that "adopt reactive states" under stress. It reports that gene-activity studies in patients and disease models point to "many putative reactive sub-states" of astrocytes, and that how far these are shared across diseases "is unclear." It is a review with no new data and reports no treatment, cure or prevention.
Study details
- Evidence strengthLow
How this study scored 56/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Nature reviews. Neurology) |
| Journal's citation record | 3 / 4 | Nature Reviews Neurology: journal h-index 269 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 516 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 103.2 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | 5 / 6 | Cited 21.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 13 other studies in this library |
| Still being cited | 4 / 4 | Cited 489 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Shane A. Liddelow: h-index 53 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 8 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 37308616) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 56 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1038/s41582-023-00822-1
- PubMed: 37308616
- Original source →
- Free full text: UCL Discovery (University College London) →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
13 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Inflammation and the immune system from nearby years
Also tagged “tdp-43”
1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.